Immutep — Prima BioMed — Corporate Update (May 2014)

4 slides from Immutep's corporate update, May 9, 2014

Slide 1: Investor Update
Investor U pdate » SP PRIMA BIOMED
Slide 2: Ovarian cancer burden and unmet need for CVac maintenance therapy
Ovarian cancer is the seventh most common cancer in women worldwide in terms of new cases diagnosed (238,719 in 2012) and including previously diagnosed patients based on the 5 year prevalence data (586,624 in 2012), the sixth most common in women worldwide.(GLOBOCAN 2012 database http://globocan.ia
Slide 3: A patient's journey with CVac
| L_| GY PRIMA BIOMED A patient's journey with CVac Sarah’sstory: CVac blood cell collection —s ; ts bers er son Fade sere cone ign. * Be con ees ul \ re an eraser ee wy Cancor Contr. Tho weok before my procedure, [wont tthe blood. Thero i 69 much paperwerk in hosptle and this s0omed tbo parlor te o
Slide 4: Company calendar and upcoming catalysts; Prima BioMed Fast Facts
® PRIMA BIOMED Company calendar and upcoming catalysts | Prima BioMed - Fast Facts simay 2016 | pres = Ustnes S1 MAY 2014 'PRR, NASDAQ: PEMD, SIN: US74354 cn Capt Orinaysares > cuertertyconferance oli 18850384 (ap 331 Mar 2014) x Cash Postion {S25 74M (approximate 0 of 1 March 2014) > wo primabiomed